Subscribe to RSS
Download PDF
DOI: 10.1055/a-2592-8456
Diabetes mellitus und Herz
Authors
Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.
-
Neuerung 1: Es sollte ein systolischer Blutdruck von 120–129mmHg angestrebt werden.
-
Begründung: In der kürzlich veröffentlichten BROAD-Studie zeigte sich bei Patienten mit Typ-2-Diabetes in der Gruppe mit intensiver Blutdrucksenkung (121,6mmHg versus 133,2mmHg in der Standardgruppe) eine signifikante Reduktion des primären Endpunkts aus nicht-fatalem Schlaganfall, nicht-fatalem Myokardinfarkt, Hospitalisierung aufgrund von Herzinsuffizienz oder kardiovaskulärem Tod [1]. Diese Daten unterstützen zudem die 2024 ESC-Leitlinienempfehlung zum Management der arteriellen Hypertonie mit einem generellen Blutdruckziel von 120–129mmHg systolisch für die meisten Patienten [2].
-
Neuerung 2: Zur Risikostratifizierung des Thromboembolie-Risikos bei Vorhofflimmern/Vorhofflattern wird der CHA2DS2-VA Score verwendet ([Tab. 2]).
-
Begründung: In der 2024 erschienen ESC-Leitlinie zum Management von Vorhofflimmern wurde die Definition des CHA2DS2-VASc-Score überarbeitet. Die Kategorie des Geschlechtes (S) ist entfallen, da dies von den Autoren als altersbedingter Risikofaktor und weniger geschlechtsspezifisch gewertet wurde.
-
Stützende Quellenangabe: [3]
Publication History
Received: 26 June 2025
Accepted: 26 June 2025
Article published online:
24 December 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
Literatur
- 1 Mebazaa A, Davison B, Chioncel O. et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022; 400: 1938-1952
- 2 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385: 1451-1461
- 3 Solomon SD, McMurray JJV, Claggett BE. et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387: 1089-1098
- 4 Di Angelantonio E, Kaptoge S. Emerging Risk Factors C et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA 2015; 314: 52-60
- 5 Marx N, Federici M, Schütt K. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023; 44: 4043-4140
- 6 Bi Y, Li M, Liu Y. et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med 2025; 392: 1155-1167
- 7 Mcevoy JW, Mccarthy CP, Bruno RM. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024; 45 (38) 3912-4018
- 8 MCGuire DK, Shih WJ, Cosentino F. et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol 2023; 6: 148-158
- 9 Sattar N, Lee MMY, Kristensen SL. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653-662
- 10 Mcguire DK, Marx N, Mulvagh SL. et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med 2025; 392 (20) 2001-2012
- 11 Marx N, Deanfield JE, Mann JFE. et al. Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation 2025; 151 (23) 1639-1650
- 12 Nichols GA, Gullion CM, Koro CE. et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884
- 13 MacDonald MR, Petrie MC, Varyani F. et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385
- 14 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021; 42: 3599-3726
- 15 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008
- 16 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383: 1413-1424
- 17 Zannad F, Ferreira JP, Pocock SJ. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020; 396: 819-829
- 18 Mcdonagh TA, Metra M, Adamo M. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44: 3627-3639
- 19 Packer M, Zile MR, Kramer CM. et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2025; 392 (05) 427-437
- 20 Pitt B, Filippatos GD, Agarwal R. et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385: 2252-2263
- 21 Bakris GL, Agarwal R, Anker SD. et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383: 2219-2229
- 22 Agarwal R, Filippatos G, Pitt B. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484
- 23 Solomon SD, McMurray JJV, Vaduganathan M. et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2024; 391 (16) 1475-1485
- 24 Van Gelder C. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414